CLINICAL TRIALS PROFILE FOR THALIDOMIDE

505(b)(2) Clinical Trials for thalidomide

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00116961 ↗	Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma	Completed	University of Michigan Cancer Center	Phase 2	2005-06-01	This is a research study for patients with newly diagnosed multiple myeloma. Multiple myeloma remains a non-curable disease however, newer medications and their combinations appear to provide higher response rates and higher complete response rates than current treatment options. One of the new medications in multiple myeloma is Velcade. Preliminary results from a study using a combination of Velcade with Doxil have shown high response rates (disease reduction). Preliminary results also show that an addition of dexamethasone to Velcade in patients not responding to Velcade alone showed improved response rates. This study involves treatment with a new combination of three standard medications: Velcade, Doxil, and dexamethasone (VDd combination). The proposed combination of all three drugs may improve efficacy and response. Velcade is approved by the Food and Drug Administration (FDA) for treatment in multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. Velcade is still currently under investigation for other indications. Doxil is not approved for use in multiple myeloma but is an approved drug for use in patients with some other cancers. Several published clinical trials provide evidence that Doxil is an active agent in multiple myeloma and it is used in treatment combinations for multiple myeloma in general practice. Dexamethasone is a standard therapy for multiple myeloma, but is not approved by the FDA for that use. The combination of all three drugs is experimental (not FDA approved). The goals of this study are to determine if this new combination therapy with Velcade, Doxil and dexamethasone is an effective treatment and also to determine the side effects that occur when this combination treatment is given.
New Combination	NCT00116961 ↗	Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma	Completed	University of Michigan Rogel Cancer Center	Phase 2	2005-06-01	This is a research study for patients with newly diagnosed multiple myeloma. Multiple myeloma remains a non-curable disease however, newer medications and their combinations appear to provide higher response rates and higher complete response rates than current treatment options. One of the new medications in multiple myeloma is Velcade. Preliminary results from a study using a combination of Velcade with Doxil have shown high response rates (disease reduction). Preliminary results also show that an addition of dexamethasone to Velcade in patients not responding to Velcade alone showed improved response rates. This study involves treatment with a new combination of three standard medications: Velcade, Doxil, and dexamethasone (VDd combination). The proposed combination of all three drugs may improve efficacy and response. Velcade is approved by the Food and Drug Administration (FDA) for treatment in multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. Velcade is still currently under investigation for other indications. Doxil is not approved for use in multiple myeloma but is an approved drug for use in patients with some other cancers. Several published clinical trials provide evidence that Doxil is an active agent in multiple myeloma and it is used in treatment combinations for multiple myeloma in general practice. Dexamethasone is a standard therapy for multiple myeloma, but is not approved by the FDA for that use. The combination of all three drugs is experimental (not FDA approved). The goals of this study are to determine if this new combination therapy with Velcade, Doxil and dexamethasone is an effective treatment and also to determine the side effects that occur when this combination treatment is given.
New Combination	NCT02188368 ↗	Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients	Active, not recruiting	Celgene Corporation	Phase 2	2014-08-01	The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma (MM). Pomalidomide (alone or in combination with dexamethasone) has been approved by the United States Food and Drug Administration (FDA) for the treatment of MM patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of their last therapy. However, the use of pomalidomide in combination with other drugs used to treat MM, such as chemotherapeutic agents and proteasome inhibitors, is currently being tested and is not approved. Pomalidomide is in the same drug class as thalidomide and lenalidomide. Like lenalidomide, pomalidomide is a drug that alters the immune system and it may also interfere with the development of small blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. The testing done with pomalidomide thus far has shown that it is well-tolerated and effective for subjects with MM both on its own and in combination with dexamethasone. Using another drug class, namely proteasome inhibitors, we have demonstrated that simply replacing a proteasome inhibitor with another in an established anti-myeloma treatment regimen can frequently overcome resistance regardless of the other agents that are part of the anti-myeloma regimen. Importantly, the toxicity profile of the new combinations closely resembled that of the proteasome inhibitor administered as a single agent. Based on this experience, we hypothesize that the replacement of lenalidomide with pomalidomide will yield similar results in a similar relapsed/refractory MM patient population.
New Combination	NCT02188368 ↗	Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients	Active, not recruiting	Oncotherapeutics	Phase 2	2014-08-01	The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma (MM). Pomalidomide (alone or in combination with dexamethasone) has been approved by the United States Food and Drug Administration (FDA) for the treatment of MM patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of their last therapy. However, the use of pomalidomide in combination with other drugs used to treat MM, such as chemotherapeutic agents and proteasome inhibitors, is currently being tested and is not approved. Pomalidomide is in the same drug class as thalidomide and lenalidomide. Like lenalidomide, pomalidomide is a drug that alters the immune system and it may also interfere with the development of small blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. The testing done with pomalidomide thus far has shown that it is well-tolerated and effective for subjects with MM both on its own and in combination with dexamethasone. Using another drug class, namely proteasome inhibitors, we have demonstrated that simply replacing a proteasome inhibitor with another in an established anti-myeloma treatment regimen can frequently overcome resistance regardless of the other agents that are part of the anti-myeloma regimen. Importantly, the toxicity profile of the new combinations closely resembled that of the proteasome inhibitor administered as a single agent. Based on this experience, we hypothesize that the replacement of lenalidomide with pomalidomide will yield similar results in a similar relapsed/refractory MM patient population.

All Clinical Trials for thalidomide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000790 ↗	Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection	Completed	Andrulis Pharmaceuticals	Phase 2	1969-12-31	PRIMARY: To evaluate the effectiveness and safety of thalidomide for treatment of oral and esophageal aphthous ulcers (those unrelated to a known infection or malignancy) in patients with advanced HIV disease. To evaluate the effect of thalidomide on HIV load in this patient population. Per 06/28/94 amendment, to evaluate the effectiveness of thalidomide in preventing recurrences in patients whose aphthae completely heal at the end of acute treatment. SECONDARY: To evaluate the effect of thalidomide on blood tumor necrosis factor (TNF) levels and to obtain pharmacokinetic data on the drug. Per 06/28/94 amendment, to evaluate the safety of thalidomide. Per 05/10/95 amendment, to explore in a substudy the effects of thalidomide on idiopathic genital aphthous ulcers in HIV-infected women. Aphthous ulcers of the mouth or esophagus can interfere with eating, resulting in malnutrition and wasting. Thalidomide has been proposed as an effective therapy for severe forms of aphthous ulceration in AIDS patients.
NCT00000790 ↗	Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	PRIMARY: To evaluate the effectiveness and safety of thalidomide for treatment of oral and esophageal aphthous ulcers (those unrelated to a known infection or malignancy) in patients with advanced HIV disease. To evaluate the effect of thalidomide on HIV load in this patient population. Per 06/28/94 amendment, to evaluate the effectiveness of thalidomide in preventing recurrences in patients whose aphthae completely heal at the end of acute treatment. SECONDARY: To evaluate the effect of thalidomide on blood tumor necrosis factor (TNF) levels and to obtain pharmacokinetic data on the drug. Per 06/28/94 amendment, to evaluate the safety of thalidomide. Per 05/10/95 amendment, to explore in a substudy the effects of thalidomide on idiopathic genital aphthous ulcers in HIV-infected women. Aphthous ulcers of the mouth or esophagus can interfere with eating, resulting in malnutrition and wasting. Thalidomide has been proposed as an effective therapy for severe forms of aphthous ulceration in AIDS patients.
NCT00000812 ↗	A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection	Completed	Celgene Corporation	Phase 1	1969-12-31	PRIMARY: To evaluate the safety, tolerability, and pharmacokinetics of daily oral thalidomide. SECONDARY: To examine the effect of thalidomide on antiviral activity and tumor necrosis factor-alpha (TNF-alpha) production, and the correlation between TNF-alpha inhibition and viral burden. A protein in the blood called tumor necrosis factor (TNF-alpha) is abnormally elevated in patients with HIV infection and may cause the body to produce more virus. In vitro studies have demonstrated that thalidomide reduces TNF-alpha levels and inhibits production of HIV. However, more information on the pharmacological and immunological aspects of thalidomide is needed.
NCT00000812 ↗	A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	PRIMARY: To evaluate the safety, tolerability, and pharmacokinetics of daily oral thalidomide. SECONDARY: To examine the effect of thalidomide on antiviral activity and tumor necrosis factor-alpha (TNF-alpha) production, and the correlation between TNF-alpha inhibition and viral burden. A protein in the blood called tumor necrosis factor (TNF-alpha) is abnormally elevated in patients with HIV infection and may cause the body to produce more virus. In vitro studies have demonstrated that thalidomide reduces TNF-alpha levels and inhibits production of HIV. However, more information on the pharmacological and immunological aspects of thalidomide is needed.
NCT00001446 ↗	A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1995-09-01	This is a phase II study designed to evaluate the potential clinical efficacy of thalidomide in patients with hormone-refractory prostate cancer. An important aspect of this study is to characterize the pharmacokinetics of thalidomide, as well as make correlations between the degree of angiogenesis occurring in a patient and the activity of thalidomide.

Clinical Trial Conditions for thalidomide

Condition Name

Condition Name for thalidomide
Intervention	Trials
Multiple Myeloma	151
Multiple Myeloma and Plasma Cell Neoplasm	19
Brain and Central Nervous System Tumors	9
HIV Infections	9

Condition MeSH

Condition MeSH for thalidomide
Intervention	Trials
Multiple Myeloma	197
Neoplasms, Plasma Cell	187
Lymphoma	29
Plasmacytoma	22

Clinical Trial Locations for thalidomide

Trials by Country

Trials by Country for thalidomide
Location	Trials
United States	949
China	122
Canada	55
Italy	53
United Kingdom	44

Trials by US State

Trials by US State for thalidomide
Location	Trials
New York	79
California	45
Texas	45
Ohio	45
Arkansas	41

Clinical Trial Progress for thalidomide

Clinical Trial Phase

Clinical Trial Phase for thalidomide
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	3
PHASE2	15

Clinical Trial Status

Clinical Trial Status for thalidomide
Clinical Trial Phase	Trials
Completed	271
Unknown status	76
Terminated	64

Clinical Trial Sponsors for thalidomide

Sponsor Name

Sponsor Name for thalidomide
Sponsor	Trials
National Cancer Institute (NCI)	100
Celgene Corporation	75
University of Arkansas	30

Sponsor Type

Sponsor Type for thalidomide
Sponsor	Trials
Other	719
Industry	194
NIH	122

Thalidomide Clinical Trials Update, Market Analysis and Exclusivity Outlook (2026)

Last updated: July 27, 2026

Executive summary: Thalidomide remains marketed for multiple indications in oncology and dermatology, but new clinical readouts are incremental rather than paradigm-shifting. Commercial upside is constrained by mature use, multi-source availability of legacy brands in key geographies, and ongoing safety-driven prescribing controls. Growth projections in 2026–2031 rely mainly on label maintenance, incremental uptake in off-patent settings, and continued penetration of hematology regimens where thalidomide is used as a component of combination therapy.

What clinical trials are ongoing for thalidomide in 2026?

Answer: Clinical activity in 2026 clusters around (1) hematologic malignancies using thalidomide in combination regimens, (2) immunomodulatory use cases in inflammatory or immune-mediated diseases, and (3) regimen optimization to improve response durability and tolerability. Trial designs tend to focus on dosing schedules, combination partners, and patient selection biomarkers rather than new thalidomide-only mechanisms.

H3: Hematology trial themes for thalidomide

• Combination therapy sequencing in multiple myeloma and related plasma cell disorders (standard-of-care backbones plus IMiD-based synergy concepts)
• Real-world and prospective studies addressing thrombosis prophylaxis and neuropathy risk mitigation
• Dose and schedule refinements intended to reduce treatment discontinuation

H3: Non-oncology or immunology trial themes

• Immunomodulation in chronic inflammatory conditions using thalidomide-centered regimens
• Safety and tolerability studies in defined populations, with endpoints commonly centered on symptom scores and discontinuation rates

H3: What to look for in new readouts

• Overall response rate and progression-free survival in combination settings
• Neuropathy incidence and grade distribution
• Treatment discontinuation rates and dose reductions
• Thrombosis and thromboembolism incidence under prophylaxis protocols
• Subgroup activity by baseline disease burden and prior lines of therapy

Clinical-trials watchlist indicators for business: prioritize trials that report neuropathy outcomes and discontinuation rates, because those parameters drive net realized usage versus efficacy-only readouts.

How is thalidomide positioned in the market: current demand and revenue drivers?

Answer: Demand is anchored by established use in hematologic indications and the practical economics of an off-patent molecule. Revenue drivers depend on country-level access, availability of branded supply where controls are strict, and the ability to maintain stable prescribing under Risk Evaluation and Mitigation Strategy (REMS)-like frameworks.

H3: Key commercial revenue drivers

• Availability through multiple manufacturers and import channels in many markets
• Uptake in combination regimens where thalidomide remains cost-effective compared with newer IMiDs
• Brand-channel leverage where strict controls limit substitution
• Contracting dynamics for oncology formularies and hospital procurement

H3: Main constraints on growth

• Safety and monitoring burden (neuropathy risk, thromboembolism risk)
• Competitive pressure from newer IMiDs with more favorable safety profiles in certain settings
• Physician and payer preferences shifting with updated clinical guidelines and new combination evidence
• Mature addressable patient populations in core indications

Thalidomide market projections 2026-2031: what growth is realistic?

Answer: The most realistic projection is low-to-mid single-digit growth in value with flatter unit growth, driven primarily by pricing and mix rather than net new patient expansion. Conversion of clinical evidence into practice is typically slower for mature molecules, and safety controls cap rapid uptake.

H3: Market projection mechanics used in revenue planning

• Unit demand: incremental prescribing tied to guideline cycles and local reimbursement changes
• Pricing: net price depends on generic/brand mix, procurement frameworks, and tender cycles
• Mix: higher use of thalidomide in settings where newer agents are constrained by payer economics
• Supply stability: disruptions can temporarily change market share even when molecule-level demand is stable

H3: Scenario framing for business planning (no mechanistic hype)

• Base case (most likely): stable-to-slightly growing revenues with margin variability due to competitive pricing
• Bull case: improved tolerability data or guideline reinforcement in combination regimens increases persistence and reduces discontinuations
• Bear case: faster guideline substitution toward alternative IMiDs reduces thalidomide share in combination pathways

When does thalidomide lose exclusivity, and which IP barriers still matter?

Answer: Thalidomide’s active ingredient is off patent in the US and Europe. Persistent IP barriers are typically not on the basic molecule, but on specific formulations, manufacturing processes, and branded method-of-use or REMS-related commercialization aspects where applicable.

H3: Typical patent estate structure for mature small molecules

• Formulation patents: granulation, tablet coatings, stability and dissolution targets
• Process patents: impurity profiles, crystallization or milling processes
• Method-of-use patents: specific combination regimens or sequencing
• Packaging and controlled-distribution patents: rarely decisive, often secondary to broader IP and regulatory constraints

H3: Practical effect of off-patent status

• Generic competition is usually the default outcome once regulatory and manufacturing requirements are met.
• Remaining differentiation is driven by quality system capability, supply chain reliability, and distribution controls rather than active-ingredient exclusivity.

What patents protect thalidomide today (formulation, process, and method-of-use)?

Answer: Current patent protection that can still matter is concentrated in secondary IP domains: formulations, processes, and some method-of-use claims tied to specific regimens and patient subsets. For most markets, these are not robust enough to sustain single-agent market exclusivity for the drug itself.

H3: Formulation patents that can extend commercial lead time

• Improved dissolution or bioavailability formulations
• Stability and impurity reduction approaches tied to manufacturing control
• Patient-safety-related formulation refinements

H3: Process and quality-control patents

• Cleaner synthesis routes with tighter impurity specifications
• Crystallization polymorph control and batch reproducibility

H3: Method-of-use and combination patents

• Specific dosing schedules in combination regimens
• Line-of-therapy specific combinations
• Neuropathy mitigation strategies that are embedded in protocol-level claims

What is the Orange Book status of thalidomide products in the US?

Answer: US Orange Book listings for thalidomide are typically dominated by older entries with limited remaining patent life on the active ingredient. Commercially relevant listings usually persist only for particular branded products or specific formulation patents that were filed late or maintained with continuing scope.

H3: What to evaluate in Orange Book for business decisions

• Whether unexpired patents are listed for a specific NDC
• Patent type: drug substance, drug product, or method of use
• Expiration dates and whether any exclusivity blocks generic entry via 505(b)(2) or ANDA pathways
• Whether relevant patents are listed only for a given dosage form strength

Are there Paragraph IV challenges or generic entry risks for thalidomide?

Answer: Paragraph IV activity for thalidomide is more likely to be concentrated around specific branded NDCs where remaining patents or exclusivity exist. In general, thalidomide is a mature, off-patent molecule, so generic entry risks are typically lower where no unexpired patent coverage remains.

H3: Generic entry risk checklist used by litigators

• Identify unexpired drug product or method-of-use patents for the exact NDC
• Map claim scope to plausible generic infringement theories (formulation vs use)
• Confirm whether the branded holder has enforceable, active claims at the time of ANDA approval

What thalidomide litigation affects generics or competing branded products?

Answer: Litigation for thalidomide over the last decade has primarily tracked disputes around secondary patents (formulation/process/method-of-use) rather than the core active ingredient. Material litigation effects depend on whether a specific NDC still has enforceable, unexpired patents listed at the time of generic entry.

H3: Litigation topics to prioritize

• Claim construction on formulation/process patents
• Remedies and settlement terms that control launch timing
• Injunction scope if asserted patents remain in-force

How does thalidomide compare with lenalidomide and pomalidomide: market and safety trade-offs?

Answer: Lenalidomide and pomalidomide compete in overlapping hematologic indications, with thalidomide generally facing share pressure where newer IMiDs are preferred for efficacy-tolerability profiles. However, thalidomide remains commercially relevant where cost, availability, or regimen evidence supports use.

H3: Business comparison axes

• Price and tender competitiveness
• Neuropathy incidence and monitoring burden in prescribing workflows
• Thrombosis prophylaxis protocols and how they affect net tolerability
• Formulary acceptance across major hospital systems

What FDA regulatory status controls thalidomide prescribing in practice?

Answer: Thalidomide is administered under stringent risk controls in the US to prevent teratogenic exposure. Regulatory controls shape supply distribution and prescribing workflows, which affects market access more than conventional labeling updates.

H3: Practical regulatory constraints that affect sales planning

• Restricted distribution and certification processes
• Mandatory patient monitoring and risk management documentation
• Pregnancy prevention requirements and compliance burden
• Pharmacy handling and chain-of-custody requirements

Which companies manufacture and sell thalidomide, and how does that shape competition?

Answer: Competition is primarily driven by multi-source supply and branded distribution in jurisdictions with strict risk controls. The competitive set typically includes generic and branded suppliers with established regulatory approvals, quality systems, and distribution infrastructure for controlled REMS-like programs.

H3: Competitive landscape factors

• Contracting power with large oncology centers
• Ability to sustain supply under tightly regulated distribution
• Batch manufacturing quality and impurity control
• Throughput and compliance operations for risk-managed dispensing

What future clinical outcomes could change thalidomide’s commercial trajectory?

Answer: The commercial trajectory would most likely improve if trials demonstrate reduced neuropathy discontinuations, stronger long-term durability in combination regimens, or expanded eligibility via clearer patient-selection biomarkers.

H3: Highest-impact endpoints for market reassessment

• Lower grade 3 or higher neuropathy rates
• Reduced discontinuation due to adverse events
• Improved progression-free survival in defined subgroups
• Favorable overall survival signals that change guideline recommendations

Key Takeaways

• Thalidomide’s clinical pipeline is incremental, with most trial value tied to safety and regimen optimization rather than mechanism-breaking claims.
• Market growth is constrained by maturity, safety monitoring burden, and competition from newer IMiDs, so projections are likely value-mix driven rather than patient-count expansion.
• Active ingredient exclusivity is largely exhausted; remaining IP leverage is typically in formulation/process/method-of-use niches and specific NDC coverage that can delay generic entry only if still unexpired.
• Commercial planning should weight controlled-distribution compliance capabilities and persistence (treatment continuation) as much as efficacy endpoints.

FAQs

1) What are thalidomide’s most common adverse effects that impact real-world persistence?
Neuropathy, constipation, sedation/fatigue, and thromboembolic events drive dose modifications, monitoring intensity, and treatment discontinuation.

2) Does thalidomide have REMS or equivalent risk controls in the US?
Yes, thalidomide is subject to stringent pregnancy-prevention and controlled dispensing requirements in the US.

3) What NDCs are most relevant for generic competition risk if patents still list for specific formulations?
Generic risk should be evaluated NDC-by-NDC using Orange Book drug product and method-of-use patent listings.

4) Are there trials combining thalidomide with other agents to improve response duration?
Yes, the most active clinical programs generally use thalidomide as a combination backbone, targeting improved durability and tolerability.

5) How do neuropathy mitigation strategies affect dosing and market usage?
Protocols that reduce severe neuropathy and extend treatment duration improve persistence, which tends to matter more commercially than small efficacy gains.

References (APA)

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. ClinicalTrials.gov. Thalidomide. U.S. National Library of Medicine.
3. FDA label and risk management materials for thalidomide-containing products. U.S. Food and Drug Administration.